BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kateera F, Shumbusho F, Manirambona L, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Kabakambira JD, Sylvain H, Camus G, Grant PM, Gupta N. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:533-41. [DOI: 10.1016/s2468-1253(21)00398-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Akiyama MJ, Nyakowa M, Riback LR, Cherutich P, Kurth AE. HCV genotype 4 subtypes in people who inject drugs in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022;7:699. [DOI: 10.1016/s2468-1253(22)00175-3] [Reference Citation Analysis]
2 Zhou Z, Zhang J, Zhou E, Ren C, Wang J, Wang Y. Small molecule NS5B RdRp non-nucleoside inhibitors for the treatment of HCV infection: A medicinal chemistry perspective. Eur J Med Chem 2022;240:114595. [PMID: 35868125 DOI: 10.1016/j.ejmech.2022.114595] [Reference Citation Analysis]
3 Gupta N, Manirambona L, Shumbusho F, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Mukabatsinda C, Musabeyezu E, Camus G, Grant PM, Kateera F. Safety and efficacy of sofosbuvir–velpatasvir–voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial. The Lancet Gastroenterology & Hepatology 2022;7:542-51. [DOI: 10.1016/s2468-1253(21)00399-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
4 Opio CK. Direct-acting antiviral regimens and HCV treatment failure and re-treatment in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022;7:498-9. [DOI: 10.1016/s2468-1253(21)00465-9] [Reference Citation Analysis]